Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 13/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6786207 | 0.98 | PDE5A (0.66) | PDE5AALDH1A1PDE1BMEN1MAPT | |
| SCHEMBL857392 | 0.84 | ALDH1A1 (0.53) | PDE5AALDH1A1PDE1BMEN1MAPT | |
| SCHEMBL12143431 | 0.82 | PDE5A (0.68) | PDE5APDE1B | |
| SCHEMBL857052 | 0.81 | PDE1B (0.54) | PDE5AALDH1A1PDE1BMEN1MAPT | |
| SCHEMBL30605542 | 0.81 | PDE1B (0.54) | PDE5AALDH1A1PDE1BMEN1MAPT | |
| SCHEMBL7797438 | 0.79 | PDE5A (0.50) | PDE5AALDH1A1PDE1BMEN1MAPT | |
| SCHEMBL14671423 | 0.79 | POLB (0.50) | PDE5AALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL12844131 | 0.78 | PDE5A (0.62) | PDE5AALDH1A1PDE1B | |
| SCHEMBL12775449 | 0.78 | PDE5A (0.62) | PDE5APDE1B | |
| SCHEMBL29091635 | 0.78 | ALDH1A1 (0.48) | PDE5AALDH1A1PDE1BMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640392-B1 | SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2015-01-07 | — | — | EP | disclosed |
| US-8815879-B2 | Substituted 4-(selenophen-2(or-3)-ylamino)pyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130266563-A1 | SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2013-10-10 | — | — | US | disclosed |
| EP-2640392-A2 | SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2013-09-25 | — | — | EP | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012066578-A2 | SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| EP-0669324-A1 | QUINAZOLINE COMPOUND | Eisai Co., Ltd. (JP) | 1995-08-30 | — | — | EP | disclosed |
| EP-0638567-A1 | ADENOSINE INCORPORATION INHIBITOR | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1995-02-15 | — | — | EP | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| CN-1071164-A | Nitrogen-containing heterocycle compound | EISAI CO LTD (JP) | 1993-04-21 | — | — | CN | disclosed |
| EP-0310155-A1 | Heteroaryl substituted aminomethyl benzene derivatives, compositions and use | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0114878-A4 | PHTHALAZINE SUBSTITUTED AMINOMETHYL BENZENE DERIVATIVES, COMPOSITIONS AND USE. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1986-03-18 | — | — | EP | disclosed |
| US-4466965-A | ANTIARRMYTHMIA AGENTS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1984-08-21 | — | — | US | disclosed |
| EP-0114878-A1 | PHTHALAZINE SUBSTITUTED AMINOMETHYL BENZENE DERIVATIVES, COMPOSITIONS AND USE. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1984-08-08 | — | — | EP | disclosed |
| WO-1984000489-A1 | HETEROARYL SUBSTITUTED AMINOMETHYL BENZENE DERIVATIVES, COMPOSITIONS AND USE | AMERICAN HOSPITAL SUPPLY CORP (US) | 1984-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266563-A1 | SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | RPS6, SULT1E1, SCLY | PDE5A 4506/4885ALDH1A1 2281/4885PDE1B 4504/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | PDE5A 1359/4885ALDH1A1 3049/4885PDE1B 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.